---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-023698"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T10:32:23.734997+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# DiaMedica Therapeutics Q2 2023: clinical hold lifted, $37.5M private placement, cash $60.7M

## Summary
- FDA fully lifted clinical hold on ReMEDy2 Phase 2/3 trial of DM199 for acute ischemic stroke on June 21, 2023.
- Completed $37.5M private placement (~11M shares at $3.40; net proceeds ~$36.1M); cash runway into 2026.
- Cash, cash equivalents and investments of $60.7M as of June 30, 2023, up from $33.5M at Dec 31, 2022.
- R&D expenses increased to $6.2M for H1 2023 (up from $3.9M) due to clinical hold resolution and Phase 1C study.
- Phase 1C study in ACEi patients completed; all received full IV dose with no hypotension.

## SEC filing metadata
- accession: 0001437749-23-023698
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774923023698/0001437749-23-023698-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774923023698/dmtp20230814_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-023698
- JSON: https://secwatch.observer/filing/0001437749-23-023698.json
- Plain text: https://secwatch.observer/filing/0001437749-23-023698.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.